Daewoong Pharmaceutical said Wednesday it has won regulatory approval in Indonesia for its type 2 diabetes treatment Envlo (enavogliflozin), marking its entry into Southeast Asia’s largest pharmaceutical market.
The drug was approved by Indonesia’s National Agency of Drug and Food Control, Dae
Continue Reading on The Korea Herald
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.